Adverum Biotechnologies (ADVM) Reaches $2.72 52-Week Low, India Globalization Capital (NYSEMKT:IGC) Shorts Raised By 324.17%

India Globalization Capital Incorporated (NYSEMKT:IGC) had an increase of 324.17% in short interest. IGC’s SI was 50,900 shares in March as released by FINRA. Its up 324.17% from 12,000 shares previously. With 91,800 avg volume, 1 days are for India Globalization Capital Incorporated (NYSEMKT:IGC)’s short sellers to cover IGC’s short positions. The SI to India Globalization Capital Incorporated’s float is 0.21%. About 288,555 shares traded. India Globalization Capital, Inc. (NYSEMKT:IGC) has declined 12.00% since August 11, 2016 and is downtrending. It has underperformed by 20.81% the S&P500.

The stock of Adverum Biotechnologies Inc (NASDAQ:ADVM) hit a new 52-week low and has $2.61 target or 4.00% below today’s $2.72 share price. The 6 months bearish chart indicates high risk for the $114.62M company. The 1-year low was reported on Mar, 20 by Barchart.com. If the $2.61 price target is reached, the company will be worth $4.58M less. About 118,912 shares traded. Adverum Biotechnologies Inc (NASDAQ:ADVM) has declined 39.29% since August 11, 2016 and is downtrending. It has underperformed by 48.10% the S&P500.

Analysts await Adverum Biotechnologies Inc (NASDAQ:ADVM) to report earnings on May, 5. They expect $-0.30 EPS, up 47.37% or $0.27 from last year’s $-0.57 per share. After $-0.27 actual EPS reported by Adverum Biotechnologies Inc for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The company has market cap of $114.62 million. The Firm is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. It currently has negative earnings. The Firm operates and manages its business in the segment of developing and commercializing gene therapeutics.

India Globalization Capital, Inc. develops intellectual property for the treatment of life altering or life threatening conditions, through its research on phytocannabinoid therapies, in the United States. The company has market cap of $11.55 million. The Firm manufactures farming facilities for leasing. It currently has negative earnings. In India and China, the Company leases equipment, trade commodities and electronic components, and in Malaysia, it focuses to develop, manage and sell residential and commercial real estate.